Home›Clinical trials›Ohio

GLP-1 clinical trials in Ohio: 28 recruiting now

By John Samaras, EditorRegistry checked September 4, 2026

28 GLP-1 clinical trials are recruiting at 42 sites in 17 cities across Ohio. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Ohio

  1. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

    Phase 4. Run by Brigham and Women's Hospital. Registry number NCT05390892.

    A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

    Who can join. Adults 40 to 80, have type 2 diabetes.

    1 site in Ohio

  2. Fibrosis Lessens After Metabolic Surgery

    Phase 4. Run by The Cleveland Clinic. Registry number NCT06374875.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people reduce liver fat.

    Who can join. Adults 18 to 75, have fatty liver disease (MASLD) with liver scarring (fibrosis), BMI 35+.

    1 site in Ohio

    • Cleveland Clinic, Cleveland

  3. A Phase 4, Prospective, Open-Label, Single Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Run by Eli Lilly and Company. Registry number NCT06857942.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people calm psoriasis.

    Who can join. Adults 18+, have psoriasis, BMI 27+.

    1 site in Ohio

  4. A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab

    Phase 4. Run by Eli Lilly and Company. Registry number NCT06864026.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people ease psoriatic arthritis.

    Who can join. Adults 18+, have psoriatic arthritis, BMI 27+.

    1 site in Ohio

    • Paramount Medical Research & Consulting, LLC, Middleburg Heights. 440-826-0742

  5. Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

    Phase 4. Run by The Cleveland Clinic. Registry number NCT07058155.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people reduce liver fat.

    Who can join. Adults 18 to 70, have liver cirrhosis, BMI 35+.

    1 site in Ohio

  6. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

    4 sites in Ohio

    • The Ohio State University Wexner Medical Center, Columbus. 833-602-2368
    • Great Lakes Gastroenterology, Mentor. 833-602-2368
    • ObjectiveHealth-DSI Research - Springboro, LLC, Springboro. 833-602-2368
    • Northshore Gastroenterology Research, Westlake. 833-602-2368

  7. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632457.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    4 sites in Ohio

    • The Ohio State University Wexner Medical Center, Columbus. 833-602-2368
    • Great Lakes Gastroenterology, Mentor. 833-602-2368
    • ObjectiveHealth-DSI Research - Springboro, LLC, Springboro. 833-602-2368
    • Northshore Gastroenterology Research, Westlake. 833-602-2368

  8. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

    A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

    4 sites in Ohio

    • Akron Gastro Research, Akron
    • Dayton Gastroenterology - Beavercreek, Beavercreek. 937-320-5050
    • Clinical Research Institute of Ohio - Brooklyn, Brooklyn. 440-363-4000
    • CRIOH, Westlake. 440-363-4000

  9. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT07754461.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    3 sites in Ohio

    • Diabetes & Endocrinology Associates of Stark County, Canton. 833-602-2368
    • Advanced Medical Research - Maumee, Maumee. 833-602-2368
    • New Venture Medical Research, Wadsworth. 833-602-2368

  10. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06672549.

    A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

    Who can join. Children and teens 6 to 17, have obesity.

    2 sites in Ohio

    • Cleveland Clinic, Cleveland
    • Nationwide Children's Hospital, Columbus

  11. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07253285.

    A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

    Who can join. Children and teens 8 to 18, are overweight.

    2 sites in Ohio

    • Centricity Research - Ohio, Columbus
    • PriMed Clinical Research, Dayton

  12. Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH

    Phase 3. Run by Altimmune, Inc. Registry number NCT07795164.

    A study testing whether a GLP-1 and glucagon medicine from Altimmune, pemvidutide, can help people reduce liver fat.

    Who can join. Adults 18 to 75, have fatty liver disease (also called MASH or NASH), BMI 23+.

    2 sites in Ohio

    • Altimmune Clinical Study Site, Springboro
    • Altimmune Clinical Study Site, Westlake

  13. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937086.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

    Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

    1 site in Ohio

    • Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake

  14. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

    Phase 3. Run by Eli Lilly and Company. Registry number NCT06937099.

    A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

    Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

    1 site in Ohio

    • Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake

  15. Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

    Phase 3. Run by VA Office of Research and Development. Registry number NCT07218354.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with alcohol use disorder drink less.

    Who can join. Adults 18 to 80, have alcohol use disorder, BMI 21+.

    1 site in Ohio

    • Louis Stokes VA Medical Center, Cleveland, OH, Cleveland. 216-231-3241

  16. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07564414.

    A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

    Who can join. Adults 18+, have obesity, BMI 35+.

    1 site in Ohio

    • Advanced Medical Research, Maumee

  17. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. Run by AstraZeneca. Registry number NCT07662213.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Ohio

    • Research Site, Columbus

  18. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06143956.

    A study testing whether an investigational medicine from Lilly, LY3305677, can help people lose weight.

    Who can join. Adults 18 to 75, have obesity, BMI 27+.

    1 site in Ohio

  19. TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

    Phase 2. Run by The Cleveland Clinic. Registry number NCT06802081.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with atrial fibrillation lose weight.

    Who can join. Adults 18 to 80, have atrial fibrillation, BMI 27+.

    1 site in Ohio

  20. A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

    Phase 2. Run by Eli Lilly and Company. Registry number NCT06897475.

    A study testing whether an investigational medicine from Lilly, LY3457263, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes, BMI 27+.

    1 site in Ohio

    • Providence Health Partners-Center for Clinical Research, Dayton. 937-297-8994
The other 8 studies recruiting in Ohio

  1. Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)

    Phase 2. Run by Mansa. Registry number NCT07029009.

    A study testing whether a GLP-1 medicine, liraglutide, can help people with maturity-onset diabetes of the young (MODY) lower blood sugar.

    Who can join. Ages 10+, have maturity-onset diabetes of the young (MODY), BMI 18.5+.

    1 site in Ohio

    • Cincinnati Children's Hospital Medical Center, Cincinnati. 513-636-0002

  2. A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07415954.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    1 site in Ohio

    • Providence Center for Clinical Research, Dayton

  3. Phase 2 Randomized, Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Icovamenib in Participants

    Phase 2. Run by Biomea Fusion Inc. Registry number NCT07502508.

    A study testing whether an investigational medicine from Biomea Fusion, icovamenib, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 70, have type 2 diabetes, BMI 25+.

    1 site in Ohio

    • Diabetes and Endocrinology Associates of Stark County, Canton

  4. A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07639021.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    1 site in Ohio

    • Family Practice Center of Wadsworth Inc., Wadsworth

  5. Preoperative Weight Loss for Open Abdominal Wall Reconstruction

    Run by Benjamin T. Miller. Registry number NCT05925959.

    A study of a GLP-1 medicine, semaglutide, in people with abdominal wall hernia.

    Who can join. Adults 18+, have abdominal wall hernia, BMI 40+.

    1 site in Ohio

    • Cleveland Clinic Main Campus, Cleveland. 2164068573

  6. Pistachio Intake and Nutrition-Related Outcomes in Individuals on GLP-1 Therapy

    Run by Ian J. Neeland, MD. Registry number NCT07244445.

    A study listed on ClinicalTrials.gov.

    Who can join. Adults 18 to 80, have obesity or are overweight, BMI 27+.

    1 site in Ohio

    • University Hospitals Cleveland Medical Center, Clevland. 216-844-5965

  7. Dietary Peanuts and Nutrition-Related Outcomes

    Run by Ian J. Neeland, MD. Registry number NCT07244458.

    A study listed on ClinicalTrials.gov.

    Who can join. Adults 18 to 80, have obesity or are overweight, BMI 27+.

    1 site in Ohio

    • University Hospitals Cleveland Medical Center, Clevland. 216-844-5965

  8. Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists

    Run by Ohio State University. Registry number NCT07702461.

    A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with diabetes lose weight.

    Who can join. Adults 18+, have obesity or are overweight.

    1 site in Ohio

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Screening for a study can take weeks. If you need the drug now, Strut Health is the cheapest cash route on the chart, from $149 a month. That price buys compounded semaglutide, a pharmacy-made version that is not FDA-approved and is not Wegovy, Ozempic, Zepbound or Mounjaro.

Visit Strut Health ↗

Clinical trials by state

Every state with a GLP-1 study recruiting today. 48 of them.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.